<DOC>
	<DOCNO>NCT01739582</DOCNO>
	<brief_summary>To determine safety profile Androxal men secondary hypogonadism .</brief_summary>
	<brief_title>An Extension Study Enclomiphene Citrate Treatment Men With Secondary Hypogonadism</brief_title>
	<detailed_description>This study open-label , multi-center Phase 3 extension study evaluate safety continue treatment Androxal subject complete either ZA-301 ZA-302 . The study require 6 study visit ( 1 eye exam ) approximately 7 month duration . Subjects treat 26 week , start daily dose 12.5 mg. At Visit 2 ( Week 6 ) subject achieve morning T value ≥450 ng/dL up-titrated 25 mg. Safety assess physical visual acuity exam , slit lamp fundoscopy , refraction eye exam , clinical laboratory test adverse event reporting .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>• Successful completion either ZA301 ZA302 • Any condition , opinion Investigator , would make Subject unsuitable candidate enrollment study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>